Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Abelacimab versus dalteparin for cancer-associated VTE in patients with gastrointestinal or genitourinary cancer
2021-003085-12Phase 3Active
- Sponsor
- Anthos Therapeutics
- Start
- Feb 2022
- Modality
- Recombinant Proteins and Enzymes, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in venous thromboembolism (VTE) comparing Abelacimab with Dalteparin sodium (2 arms). Primary endpoint: Time to first event of centrally adjudicated VTE recurrence. Started Feb 2022; status: active.
02
Drugs
abelacimabdalteparin
03
Conditions
venous thromboembolism (VTE)
Beyond the preview
Go deeper on 2021-003085-12.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-003085-12.